Articles with public access mandates - michael zalutskyLearn more
Not available anywhere: 1
Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans
JH Sampson, M Brady, R Raghavan, AI Mehta, AH Friedman, ...
Neurosurgery 69 (3), 668-676, 2011
Mandates: US National Institutes of Health
Available somewhere: 94
A plasmonic gold nanostar theranostic probe for in vivo tumor imaging and photothermal therapy
Y Liu, JR Ashton, EJ Moding, H Yuan, JK Register, AM Fales, J Choi, ...
Theranostics 5 (9), 946, 2015
Mandates: US National Institutes of Health
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors
JH Sampson, G Akabani, GE Archer, MS Berger, RE Coleman, ...
Neuro-oncology 10 (3), 320-329, 2008
Mandates: US National Institutes of Health
In situ growth of a stoichiometric PEG-like conjugate at a protein's N-terminus with significantly improved pharmacokinetics
W Gao, W Liu, JA Mackay, MR Zalutsky, EJ Toone, A Chilkoti
Proceedings of the National Academy of Sciences 106 (36), 15231-15236, 2009
Mandates: US National Institutes of Health
Astatine-211: production and availability
M R Zalutsky, M Pruszynski
Current radiopharmaceuticals 4 (3), 177-185, 2011
Mandates: US National Institutes of Health
Copper signaling axis as a target for prostate cancer therapeutics
R Safi, ER Nelson, SK Chitneni, KJ Franz, DJ George, MR Zalutsky, ...
Cancer research 74 (20), 5819-5831, 2014
Mandates: US National Institutes of Health
In situ growth of a PEG-like polymer from the C terminus of an intein fusion protein improves pharmacokinetics and tumor accumulation
W Gao, W Liu, T Christensen, MR Zalutsky, A Chilkoti
Proceedings of the National Academy of Sciences 107 (38), 16432-16437, 2010
Mandates: US National Institutes of Health
131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment
M D'Huyvetter, J De Vos, C Xavier, M Pruszynski, YGJ Sterckx, S Massa, ...
Clinical cancer research 23 (21), 6616-6628, 2017
Mandates: US National Institutes of Health, Research Foundation (Flanders)
(2S)-2-(3-(1-carboxy-5-(4-211At-astatobenzamido) pentyl) ureido)-pentanedioic acid for PSMA-targeted α-particle radiopharmaceutical therapy
AP Kiess, IL Minn, G Vaidyanathan, RF Hobbs, A Josefsson, C Shen, ...
Journal of Nuclear Medicine 57 (10), 1569-1575, 2016
Mandates: US National Institutes of Health
Molecular imaging of hypoxia
SK Chitneni, GM Palmer, MR Zalutsky, MW Dewhirst
Journal of nuclear medicine 52 (2), 165-168, 2011
Mandates: US National Institutes of Health
Protein polymer hydrogels by in situ, rapid and reversible self-gelation
D Asai, D Xu, W Liu, FG Quiroz, DJ Callahan, MR Zalutsky, SL Craig, ...
Biomaterials 33 (21), 5451-5458, 2012
Mandates: US National Institutes of Health
Injectable intratumoral depot of thermally responsive polypeptide–radionuclide conjugates delays tumor progression in a mouse model
W Liu, JA MacKay, MR Dreher, M Chen, JR McDaniel, AJ Simnick, ...
Journal of controlled Release 144 (1), 2-9, 2010
Mandates: US National Institutes of Health
Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody
M Pruszynski, E Koumarianou, G Vaidyanathan, H Revets, N Devoogdt, ...
Nuclear medicine and biology 40 (1), 52-59, 2013
Mandates: US National Institutes of Health, Research Foundation (Flanders)
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost
DA Reardon, MR Zalutsky, G Akabani, RE Coleman, AH Friedman, ...
Neuro-oncology 10 (2), 182-189, 2008
Mandates: US National Institutes of Health
Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas
Y Kato, G Vaidyanathan, MK Kaneko, K Mishima, N Srivastava, ...
Nuclear medicine and biology 37 (7), 785-794, 2010
Mandates: US National Institutes of Health
Astatine radiopharmaceuticals: prospects and problems
G Vaidyanathan, MR Zalutsky
Current radiopharmaceuticals 1 (3), 177-196, 2008
Mandates: US National Institutes of Health
Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling
M Pruszynski, E Koumarianou, G Vaidyanathan, H Revets, N Devoogdt, ...
Journal of nuclear medicine 55 (4), 650-656, 2014
Mandates: US National Institutes of Health
Injectable polypeptide micelles that form radiation crosslinked hydrogels in situ for intratumoral radiotherapy
JL Schaal, X Li, E Mastria, J Bhattacharyya, MR Zalutsky, A Chilkoti, W Liu
Journal of Controlled Release 228, 58-66, 2016
Mandates: US National Institutes of Health
Applications of 211At and 223Ra in targeted alpha-particle radiotherapy
G Vaidyanathan, M R Zalutsky
Current radiopharmaceuticals 4 (4), 283-294, 2011
Mandates: US National Institutes of Health
Preclinical evaluation of 18F-labeled anti-HER2 nanobody conjugates for imaging HER2 receptor expression by immuno-PET
G Vaidyanathan, D McDougald, J Choi, E Koumarianou, D Weitzel, ...
Journal of Nuclear Medicine 57 (6), 967-973, 2016
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program